Shore Capital Reiterates “Buy” Rating for Consort Medical (LON:CSRT)

Shore Capital reiterated their buy rating on shares of Consort Medical (LON:CSRT) in a report issued on Thursday morning, ThisIsMoney.Co.Uk reports.

Separately, Numis Securities downgraded Consort Medical to a hold rating in a research report on Thursday, June 6th.

LON CSRT opened at GBX 910 ($11.89) on Thursday. Consort Medical has a twelve month low of GBX 700 ($9.15) and a twelve month high of GBX 1,294 ($16.91). The company has a current ratio of 1.92, a quick ratio of 1.32 and a debt-to-equity ratio of 48.36. The stock has a market cap of $442.01 million and a price-to-earnings ratio of 26.69.

The company also recently declared a dividend, which will be paid on Friday, October 25th. Shareholders of record on Thursday, September 19th will be given a dividend of GBX 13.80 ($0.18) per share. This is an increase from Consort Medical’s previous dividend of $7.60. The ex-dividend date of this dividend is Thursday, September 19th. This represents a yield of 1.53%. Consort Medical’s dividend payout ratio (DPR) is presently 0.44%.

About Consort Medical

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.

Featured Article: How to use beta for portfolio diversification

Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with's FREE daily email newsletter.